Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
Portfolio Pulse from
Ocular Therapeutix has randomized over 300 patients in the SOL-1 Phase 3 trial for AXPAXLI, a treatment for wet AMD. The trial is nearing the end of its randomization phase, with topline data expected in Q4 2025. The company is also enrolling patients in a second trial, SOL-R.
December 02, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ocular Therapeutix has made significant progress in its SOL-1 Phase 3 trial for AXPAXLI, with over 300 patients randomized. This milestone could positively impact the company's stock as it demonstrates advancement in their clinical pipeline.
The successful randomization of over 300 patients in the SOL-1 trial indicates significant progress in Ocular Therapeutix's clinical development. This is a positive signal for investors as it shows the company is on track with its timelines, potentially leading to future revenue from AXPAXLI if approved.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100